Research suggests P2Y2 activation reverses hyperactivity and motor learning deficits in mice — Evidence Review
Published in Neuron, by researchers from The Ottawa Hospital, University of Ottawa
Researched by
— the AI search engine for science
Table of Contents
Researchers at The Ottawa Hospital and University of Ottawa have shown that targeting blood vessel cells in the brain can reverse certain autism-related behaviors in adult mice. Related studies largely support the idea that modulating purinergic signaling and other non-neuronal pathways can improve behavioral symptoms in animal models of autism.
- Several animal studies have found that pharmacological modulation of purinergic signaling, including targeting P2Y2 and related receptors, can improve social behavior, reduce hyperactivity, and correct metabolic disruptions in autism models, echoing the new study’s behavioral improvements in mice 1 11.
- Clinical research using purinergic antagonists such as suramin in children with autism spectrum disorder suggests safety and possible symptom improvement, though effects are variable and mechanisms may differ from the current study’s P2Y2-specific activation 2.
- The reversibility of autism-like phenotypes in adult mice has been demonstrated across different intervention strategies, including genetic, metabolic, and microbial approaches, indicating a degree of plasticity in neurodevelopmental disorders that is consistent with the new findings 9 11 12.
Study Overview and Key Findings
This study addresses a longstanding challenge in autism research: the lack of effective treatments for core behavioral symptoms, particularly in adulthood. By focusing on the brain's vasculature—specifically, the endothelial cells that line blood vessels—the research introduces a novel therapeutic target outside the traditional neuronal pathways. The work is significant because it demonstrates that correcting vascular dysfunction can reverse established behavioral abnormalities in a genetically relevant mouse model of autism, suggesting new avenues for intervention.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | The Ottawa Hospital, University of Ottawa |
| Journal Name | Neuron |
| Authors | Julie Ouellette, Sareen Warsi, Phinea Romero, Purva Khare, Shama Naz, Leya Aubert-Tandon, Moises Freitas-Andrade, Chantal Pileggi, Sozerko Yandiev, Joanna Raman-Nair, James Yee, Nicole Blakeley, Balaji Govindaswamy, Cesar Henrique Comin, Mary-Ellen Harper, Devika Soundara Manickam, Fabrice Dabertrand, Armen Saghatelyan, Baptiste Lacoste |
| Population | Adult mice with 16p11.2 deletion |
| Methods | Animal Study |
| Outcome | Behavioral symptoms related to autism |
| Results | Activating P2Y2 reversed hyperactivity and motor learning issues in mice. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus database, which contains over 200 million research papers. The following search queries were used to identify relevant studies:
- P2Y2 autism intervention effects
- hyperactivity motor learning in mice
- autism reversal mechanisms research
Below, we summarize key themes and findings from the related literature.
| Topic | Key Findings |
|---|---|
| How does purinergic signaling influence autism-like behaviors? | - Pharmacological modulation of purinergic pathways (e.g., suramin) can reverse social deficits and anxiety-like behaviors in animal models of autism, implicating purinergic signaling as a therapeutic target 1 11. - Clinical studies suggest that purinergic antagonists are generally safe and may improve some core symptoms in children with autism, though effects vary and more research is needed 2. |
| Can behavioral symptoms in adult animal models of autism be reversed? | - Restoration of gene expression (e.g., Shank3), metabolic correction, or pharmacological interventions can partially reverse autistic-like behaviors and metabolic disturbances even in adult mice, supporting the existence of plasticity beyond early development 9 11 12. - Sensitive periods for certain behaviors (e.g., social deficits) may extend into adulthood, allowing for effective interventions later in life 12. |
| What roles do non-neuronal cells and brain vasculature play in autism? | - Modulation of non-neuronal cell types (e.g., endothelial cells, oligodendrocyte progenitor cells) can impact both cognitive and motor functions in neurodevelopmental disorder models, highlighting the importance of brain microenvironment beyond neurons 7. - Vascular dysfunction and impaired blood flow regulation have been implicated in autism models, supporting the current study’s focus on endothelial cells 7. |
| How do genetic and environmental factors converge in autism models? | - Both genetic mutations (e.g., 16p11.2 deletion, Shank3, Nf1) and environmental exposures (e.g., valproic acid, maternal immune activation) give rise to overlapping behavioral phenotypes and can be ameliorated through interventions targeting shared molecular pathways 1 7 9 11. - Studies suggest that interventions targeting convergent mechanisms—such as purinergic signaling—may benefit multiple autism subtypes 10. |
How does purinergic signaling influence autism-like behaviors?
Related studies provide substantial evidence that purinergic signaling plays an important role in autism-related behaviors. Animal studies using purinergic modulators such as suramin have shown improvements in social interaction, anxiety, and behavioral abnormalities, supporting the new study's finding that activating P2Y2 (a purinergic receptor) can reverse established symptoms in adult mice.
- Suramin, a non-selective purinergic antagonist, restored sociability and reduced anxiety in valproic acid-induced autism models 1.
- Clinical trials in children with autism found that low-dose suramin infusions were generally safe and showed improvements in some behavioral endpoints, although results were variable 2.
- Single-dose suramin corrected both behavioral and metabolic abnormalities in adult mouse models of autism, with purine metabolism identified as a key regulatory pathway 11.
- Purinergic modulation did not always normalize all behavioral or molecular phenotypes, indicating that responses can be pathway- and context-dependent 1 11.
Can behavioral symptoms in adult animal models of autism be reversed?
The possibility of reversing autism-like behaviors in adulthood is supported by several studies. Research shows that interventions at later stages can lead to partial or full improvement in certain behavioral and metabolic deficits, challenging the notion that such symptoms are fixed after early development.
- Re-expression of the Shank3 gene in adult mice improved social interactions and reduced repetitive behaviors, though motor and anxiety symptoms were less responsive 9.
- Single-dose antipurinergic therapy in adult mice reversed social and metabolic abnormalities, but effects diminished over time after drug washout 11.
- Sensitive periods for some behaviors, particularly social deficits, extend into adulthood, allowing for effective pharmacological treatment later in life 12.
- The degree of reversibility varies depending on the specific behavior and underlying biological mechanism targeted 9 11 12.
What roles do non-neuronal cells and brain vasculature play in autism?
Recent studies underscore the importance of non-neuronal cells, including endothelial and glial cells, in regulating behaviors relevant to neurodevelopmental disorders. The current study’s focus on brain blood vessel function aligns with emerging evidence that the brain’s microenvironment—including vasculature and glia—can influence cognitive and motor function.
- Disruption of activity-dependent oligodendroglial plasticity in mice impairs motor learning, indicating that non-neuronal cells contribute to behavioral phenotypes in genetic models of neurodevelopmental disorders 7.
- Vascular dysfunction, as addressed by the new study through P2Y2 activation, represents a previously underexplored therapeutic target in autism research 7.
- Interventions targeting these cell types can lead to improvements in behavioral outcomes, supporting a broader focus beyond neuronal signaling 7.
- The interplay between neuronal and non-neuronal mechanisms may be critical for effective intervention strategies in autism and related disorders 7.
How do genetic and environmental factors converge in autism models?
Multiple animal models of autism—driven by both genetic and environmental factors—exhibit overlapping behavioral abnormalities, and research indicates that these can be ameliorated by targeting shared molecular pathways. The current study’s use of a genetic model (16p11.2 deletion) and targeting of a common signaling pathway reflects this convergence.
- Genetic mutations (e.g., Shank3, 16p11.2, Nf1) and environmental exposures (e.g., valproic acid, maternal immune activation) both lead to autism-like phenotypes in mice 1 7 9 11.
- Interventions aimed at shared pathways (such as purinergic signaling or synaptic plasticity) have been effective across different models, suggesting common underlying mechanisms 1 10 11.
- The reversibility of certain behavioral symptoms in adulthood is observed in both genetic and environmental models, though the extent of recovery can vary 9 11 12.
- Literature reviews highlight the importance of identifying points of convergence for developing broad-spectrum therapeutic interventions 10.
Future Research Questions
While this study opens new avenues for autism research by demonstrating reversibility of certain behavioral symptoms through vascular interventions, several questions remain about the mechanisms, translation to humans, and long-term effects. Further investigation will be needed to clarify these issues and to optimize potential therapies.
| Research Question | Relevance |
|---|---|
| Does P2Y2 activation improve core autism symptoms in humans? | Translation from mouse models to clinical populations is a key step; currently, clinical studies have focused on other purinergic modulators, and it remains unknown if P2Y2-specific activation has similar effects in humans 2 11. |
| What are the long-term effects of P2Y2 activation in mammalian brains? | The duration and sustainability of behavioral improvements after P2Y2 activation are unknown; previous studies with suramin showed reversibility but also relapse after drug washout, highlighting the need for long-term studies 11. |
| Can early-life P2Y2 activation prevent autism-like behaviors? | The study suggests that timing of intervention may influence outcomes; testing earlier activation could clarify whether developmental windows exist for optimal efficacy 12. |
| How do endothelial cell dysfunctions contribute to autism pathophysiology? | Understanding the mechanistic role of endothelial cells could reveal additional targets and clarify how vascular dysfunction interacts with neuronal circuits in autism models 7. |
| Are there shared molecular pathways between vascular and neuronal interventions in ASD? | Identifying convergence between vascular and neuronal mechanisms could lead to multi-targeted therapies and improve treatment outcomes across different autism subtypes 10. |